- Home
- KMI vs XOMAP Comparison
KMI vs XOMAP Comparison
Compare KMI & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- XOMAP
- Stock Information
- Founded
- KMI 1936
- XOMAP N/A
- Country
- KMI United States
- XOMAP United States
- Employees
- KMI N/A
- XOMAP 13
- Industry
- KMI Natural Gas Distribution
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- XOMAP Health Care
- Exchange
- KMI Nasdaq
- XOMAP Nasdaq
- Market Cap
- KMI 58.3B
- XOMAP N/A
- IPO Year
- KMI 2011
- XOMAP N/A
- Fundamental
- Price
- KMI $25.92
- XOMAP $26.25
- Analyst Decision
- KMI Buy
- XOMAP
- Analyst Count
- KMI 13
- XOMAP 0
- Target Price
- KMI $31.23
- XOMAP N/A
- AVG Volume (30 Days)
- KMI 15.6M
- XOMAP N/A
- Earning Date
- KMI 10-22-2025
- XOMAP N/A
- Dividend Yield
- KMI 4.51%
- XOMAP N/A
- EPS Growth
- KMI 7.28
- XOMAP N/A
- EPS
- KMI 1.22
- XOMAP N/A
- Revenue
- KMI $16,416,000,000.00
- XOMAP N/A
- Revenue This Year
- KMI $11.56
- XOMAP N/A
- Revenue Next Year
- KMI $5.11
- XOMAP N/A
- P/E Ratio
- KMI $21.24
- XOMAP N/A
- Revenue Growth
- KMI 8.35
- XOMAP N/A
- 52 Week Low
- KMI $23.94
- XOMAP N/A
- 52 Week High
- KMI $31.48
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- KMI 35.82
- XOMAP 49.30
- Support Level
- KMI $25.60
- XOMAP $26.00
- Resistance Level
- KMI $26.40
- XOMAP $26.47
- Average True Range (ATR)
- KMI 0.56
- XOMAP 0.13
- MACD
- KMI -0.09
- XOMAP -0.04
- Stochastic Oscillator
- KMI 12.67
- XOMAP 32.26
About KMI Kinder Morgan Inc.
Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.